Roth/ MKM sets USD 3.00 target for Rapid Micro Biosystems stock

Published on 10/14/2026 at 06:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roth/MKM set USD 3.00 target on September 29, 2026. For Rapid Micro Biosystems stock, second-quarter revenue rose 11.00 percent to USD 8.05 million.

Analyst target and reporting date

Roth/MKM began coverage with a USD 3.00 target on September 29, 2026.
Second-quarter revenue reached USD 8.05 million, up 11.00 percent year over year.
Rapid Micro Biosystems was last at USD 0.87 on Nasdaq on October 13, 2026 at 4:00 p.m. EDT.
The company is expected to report third-quarter results on November 6, 2026.

RPID, US75340L1044, Illustration mit AI erstellt.

Rapid Micro Biosystems (ISIN US75340L1044) received a USD 3.00 price target from Roth/MKM on September 29, 2026, when the firm began coverage with a Buy rating, according to Investing.com. The target contrasts with the companys continuing quarterly losses and makes execution on Growth Direct placements central to the investment case.

Three dates shape the setup

On August 7, 2026, Rapid Micro Biosystems reported second-quarter revenue of USD 8.05 million, up 11.00 percent from the second quarter of 2025, and said the 200th Growth Direct system had been placed globally, according to Rapid Micro Biosystems.

At a September 24, 2026 small-cap virtual conference, management discussed a USD 34.00 million annual revenue base, more than 50.00 percent recurring revenue and a 15.00 percent second-quarter gross margin, as reported by Investing.com. The same discussion put the installed base at 200 systems against an estimated 8,000 to 10,000 system market opportunity.

Roth/MKM then began coverage on September 29, 2026 with a USD 3.00 target, while the report said Rapid Micro Biosystems had 169 validated systems and recurring revenue above 60.00 percent of sales, according to Investing.com. The figures point to a business still building scale: recurring sales and validated systems are expanding, while profitability remains the key operational hurdle.

What does the next report test?

Rapid Micro Biosystems is expected to report third-quarter results on November 6, 2026, before the market opens, with a conference call scheduled for 8:30 a.m. ET, according to MarketBeat. The published consensus calls for USD 9.88 million in revenue and adjusted earnings per share of minus USD 0.20, giving the next report a clear test of whether growth is translating into better operating leverage.

Nasdaq price stays near yearly low

Rapid Micro Biosystems was last at USD 0.87 on Nasdaq on October 13, 2026 at 4:00 p.m. EDT. Its market capitalization was USD 39.6 million and its 52-week range was USD 0.83 to USD 4.94 as of that session, leaving the stock close to the lower end of its annual range.

Market context: Market report Nasdaq Composite.